Xtant Medical Holdings, Inc.
XTNT Healthcare Medical Devices
Xtant Medical Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $133.9 million, up 14.2% from fiscal 2024. In the quarter to June 2026, revenue fell 35.0%, EPS fell 333.3%, free cash flow fell 882.0% and total debt fell 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow XTNT
Xtant Medical Holdings, Inc. (XTNT) Beneish M-score
Xtant Medical Holdings, Inc.'s Beneish M-score for fiscal 2025 is −3.11; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −3.11 | (0.34) |
| FY2024 | −2.77 | (1.98) |
| FY2023 | −0.79 | 1.47 |
| FY2022 | −2.26 | 0.53 |
| FY2021 | −2.79 | 0.47 |
| FY2020 | −3.26 | (0.10) |
| FY2019 | −3.15 | 7.12 |
| FY2018 | −10.27 | (5.04) |
| FY2017 | −5.23 | (2.78) |
| FY2016 | −2.45 | (3.04) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.75 | — | 0.69 | |
| Gross margin index | 0.92 | — | 0.49 | |
| Asset quality index | 0.58 | — | 0.24 | |
| Sales growth index | 1.14 | — | 1.02 | |
| Depreciation index | 0.64 | — | 0.07 | |
| SG&A index | 0.84 | — | −0.14 | |
| Total accruals to total assets | (0.08) | — | −0.38 | |
| Leverage index | 0.80 | — | −0.26 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −3.11 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| RPID Rapid Micro Biosystems, Inc. compare | −5.1× |
| TLIS Talis Biomedical Corporation compare | −4.9× |
| SRTS Sensus Healthcare, Inc. compare | −3.7× |
| TELA TELA Bio, Inc. compare | −3.3× |
| XTNT Xtant Medical Holdings, Inc. | −3.1× |
| CVRX CVRx, Inc. compare | −3.0× |
| MDAI Spectral AI, Inc. compare | −2.7× |
| SNWV Sanuwave Health Inc. compare | −0.9× |
| NNOX Nano-X Imaging Ltd. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI